FDA Notifies Not to Use Gold Vigra and Miraculous Evil Root: AttorneyOne Monitor and Keep Consumers Informed

San Diego, CA (PRWEB) July 11, 2014

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Male Sexual Enhancement Products.

The FDA notified consumers on July 19, not to purchase or use Gold Vigra and Miraculous Evil Root because they contain undeclared drug ingredients. These products are promoted for male sexual enhancement and were added to a previously published list of similar products.

On June 3, the FDA published the initial list including Liu Bian Li, Eyeful, Dick's Hard Up, 3 Hard Knights, Full Throttle On Demand, GoldReallas. On June 6, the Agency added Zhen Gong Fu to this list.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds "we are determined to keep an eye on FDA announcements concerning Male Sexual Enhancement Products and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out."

As the FDA recommended "Consumers should stop using these products immediately and throw them away. Consumers who have experienced any negative side effects should consult a health care professional as soon as possible."

AttorneyOne.com has further information on Male Sexual Enhancement Products at the website including latest major drug and medical products law news.
Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/07/prweb12008157.htm

Read the full story at http://www.prweb.com/releases/2014/07/prweb12012705.htm